ROE, PBR and DOE Targets Under the 2035 Medium- to Long-Term Group Growth Scenario
First written in FY2024. 1 of 3 entries say "Reframed", first in FY2025. Latest entry: FY2026-H1.
33 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The Company formulated the Medium-Term Management Plan “INNOVATION30” (2026–2030), setting out specific strategies through 2030, and established “Business expansion and growth investment,” “Strengthening financial and capital strategies” and “Sustainability management” as its basic strategies.」
INNOVATION30の2030年に向けた計画と基本戦略が継続して示されているが、本 filing では売上高・利益率等の数値目標は再掲されていない。 - FY2025ReframedAnnual report
「＜INNOVATION30（2030年目標）＞ 売上高：700億円 化学品、化粧品ともに成長 営業利益：56億円 高付加価値事業へ傾注 営業利益率：8.0％ 安定的に８％以上 EBITDA： 90億円 「稼ぐ力」を成長させる EBITDA率：12.8％ ROS以上の成長 ROE：8.0％ 株主資本コストを安定的に上回る ROIC：6.0％ WACCを安定的に上回る PBR：1.0倍以上 早期達成を目指す DOE：3.0％以上 ３％以上かつ継続的に向上を検討」
2035年までの中長期目標体系を前半フェーズのINNOVATION30へ接続し、2030年目標として売上高700億円、営業利益56億円、ROE8.0％、ROIC6.0％、PBR1倍以上、DOE3.0％以上等を新たに示した。 - FY2024First statedAnnual report
「The Group has established ROE of at least 10% as a key target for the desired state by 2035 and introduced PBR and DOE as new management performance indicators. Desired medium- to long-term targets: revenue ¥75.0 billion; operating margin of at least 10%; ROE of at least 10%; ROIC of at least 8%; DOE of at least 3%, targeted within 2 to 3 years; and PBR of at least 1x, targeted for early achievement.」
The medium- to long-term Group growth scenario formulated in July 2024 first specifies targets through 2035 of ¥75.0 billion in revenue, operating margin of at least 10%, ROE of at least 10%, ROIC of at least 8%, DOE of at least 3% and PBR of at least 1x.